While the role of hydroxylysine and allysine have yet to be elucidated in pCAVS or fibrocalcific CAVS, inhibition of lysyl oxidase inhibitors may be an additional potential therapeutic strategy, with promising results shown related to fibroblast activation in liver fibrosis (138). This evidence concerns the gene LOX and Hepatic fibrosis.